CONTEXT

Turnover rising, hiring costs up, and a productivity signal that leadership has not yet connected to its cause.

The company is the country subsidiary of a multinational pharmaceutical group. It operates a field force of approximately 110 sales representatives across primary and specialty care, supported by medical affairs, market access, and commercial operations functions. The country P&L is €200M. The organization is established, with strong brand presence and a portfolio of both mature and recently launched products.

Over six consecutive quarters, the CHRO had tracked a deteriorating pattern in the field force. Turnover among senior representatives was accelerating. The annual exit rate in the top performance quartile had risen from a historical average of 12 percent to over 25 percent. Replacement hiring had become a continuous activity rather than a periodic one. The cost of that activity, search fees, onboarding, and the ramp time before a new rep reaches full productivity, had increased materially in the HR budget.

A parallel signal was visible in sales performance data: accounts previously managed by experienced reps were showing declining prescription trends in the quarters following a rep exit. The commercial leadership had flagged this as a market dynamics issue. The CHRO read it differently.

The exits were not random. The reps leaving were the ones with the deepest account relationships and the strongest performance histories. Their destination, in each documented case, was a competitor with a different organizational model. They were not changing careers. They were going where they could perform without the constraints they had encountered here.

The CHRO brought the TFI diagnostic to locate the structural driver and to build a quantified case for the commercial and executive leadership that had not yet connected the turnover pattern to the organization’s decision system.

DIAGNOSTIC FINDINGS

High performers leaving a system that slows them down and does not reward what they actually do.

The diagnostic engaged respondents across the senior field force, first-line managers, and commercial operations. The pattern was consistent and specific.

1. Approval cycles longer than the commercial opportunity

A senior representative identifies a high-value opportunity: a specialist with a strong prescribing history, recently accessible following a portfolio update, open to a structured medical education engagement. To act on it, the rep needs approval for a speaker program, a modified support package, or a budget allocation for an account-level initiative.

The approval path runs through the regional manager, the country medical affairs lead, and commercial operations. In cases involving pricing flexibility or tender support, legal review is required. The average elapsed time from request to decision is three to four weeks.

By the time the approval arrives, the window has closed. The specialist has moved to a different therapeutic priority. A competitor with a shorter internal decision chain has already engaged. The rep logs the outcome, starts the next cycle, and waits again.

This is not a failure of individual managers. Each approval step has a legitimate function. The problem is that the cumulative latency of the system is longer than the competitive window in which the field force is expected to operate. The organization asks its best people to move at market speed while processing their decisions at administrative speed.

2. Incentives calibrated to volume, not to value

The performance evaluation framework for field representatives is built around prescription volume: monthly and quarterly script counts by product, measured against territory targets. A rep who delivers high volume against target is recognized. A rep who invests time in a structurally complex account, pursues a high-potential specialist through a long engagement cycle, and manages the internal approval process for a custom initiative receives no differentiated recognition for that work.

The reps who experience the highest friction are precisely those who pursue the highest-value opportunities: large accounts, complex sales cycles, initiatives that require internal coordination. They generate the most organizational drag and receive the same incentive structure as reps who work straightforward, high-frequency, low-complexity territories.

The diagnostic identified this as the structural driver of the attrition pattern. The top performers are not leaving because of compensation levels. They are leaving because the system does not recognize the kind of work they do, and actively slows them down when they try to do it.

3. Friction concentrated in the top performance cohort

The TFI diagnostic measures friction across all respondents but weights outcomes against the top performance cohort: the 30 percent of the field force that generates disproportionate commercial value. In this organization, that cohort reported decision latency and incentive misalignment at levels significantly above the full-team average.

This concentration matters. Average friction across the full team would produce a different and less alarming picture. The diagnostic makes the concentration visible: the people experiencing the most friction are the ones the organization can least afford to lose.

ECONOMIC EXPOSURE

What the decision system is costing in productivity and attrition, annually.

The Clario scoring model applied to the engagement profile produced the following output:

Estimated productivity loss	approx. €924K annually
Estimated attrition risk	approx. €1.9M annually
Total friction cost (range)	€2.4M – €3.2M annually
Top performer cohort	33 reps (top 30% of field force)
Replacement cost multiplier	1.5x fully loaded annual compensation
Talent friction score	8.1 / 10

Productivity loss reflects the estimated output reduction of the top performer cohort operating under high structural friction. At a system TFI score of 8.1, the model estimates a 20 percent reduction in effective output for the top cohort relative to a low-friction environment.

Attrition risk reflects the annual cost of replacing top-quartile exits at 1.5 times fully-loaded compensation. This figure covers direct replacement costs: search, onboarding, and the productivity gap during the ramp period. It does not include the revenue impact on accounts in transition, which is visible in the commercial data but not included in the TFI output.

The CHRO had estimated the direct hiring cost increase at approximately €600K above the prior-year baseline. The TFI diagnostic reframed this figure: the €600K was the visible tip of a friction cost that the model placed between €2.4M and €3.2M annually, the majority of which was productivity loss and full replacement economics rather than search fees alone.

Presented to the country general manager and the commercial director with this framing, the diagnostic shifted the conversation. Turnover had been treated as an HR problem with an HR budget line. The diagnostic made it a commercial problem with a commercial cost.

POST-DIAGNOSTIC SITUATION

Decision authority closer to where the commercial opportunity lives.

Clario identified the structural drivers and quantified their cost. Execution remained with the client.

The diagnostic gave the CHRO a quantified case and a located cause. The commercial leadership, now operating from the same economic frame, supported two structural changes that had previously not reached the decision agenda.

Changes made

• A delegated authority framework was introduced for field commercial decisions below a defined threshold. Senior representatives with a track record above a minimum performance standard were authorized to approve speaker program budgets, account-level support packages, and territory-specific initiatives up to a defined value without regional manager sign-off. The approval chain remained intact above the threshold.
• The performance evaluation framework was revised to include a qualitative account development component alongside the existing volume metrics. Reps managing high-complexity accounts with multi-cycle engagement requirements were assessed against a separate track that weighted pipeline quality and account trajectory, not only quarterly script volume.
• A quarterly deal review process was established in which closed-won and closed-lost outcomes were analyzed against the qualification criteria at entry. Findings fed directly into the qualification model update cycle, closing the feedback loop between deal outcomes and upstream lead scoring.

Turnover rate: top performance quartile

Pre-diagnostic	12-month target	Historical baseline
approx. 25%	approx. 16%	approx. 12%

The 12-month target does not return the turnover rate to the historical baseline. The delegated authority framework and the revised evaluation criteria take time to embed. Trust with the remaining senior reps, some of whom had watched colleagues leave and were making their own assessments, rebuilds gradually rather than immediately.

The 12-month trajectory is a 36 percent reduction in the top-quartile exit rate relative to the peak. Combined with the reduction in replacement hiring activity, the projected friction cost in year two falls within the lower bound of the diagnostic range. The historical baseline is the 24-month target.

Back to use cases index